Dr. Kachaamy discusses novel cancer pain treatments and their potential impact during an investor segment featuring Autonomix Medical.
Quiver AI Summary
Autonomix Medical, Inc. recently showcased its innovative technologies aimed at treating visceral cancer pain, particularly in relation to pancreatic cancer, during a Virtual Investor segment featuring Dr. Toufic Kachaamy. As Chief of Medicine at City of Hope, Dr. Kachaamy highlighted the significance of Autonomix's data, which was presented at the Society of Surgical Oncology Annual Meeting, emphasizing its potential impact on clinical practice and its differentiation from existing treatments. The discussion also touched on the feasibility of the technology platform, which could extend beyond pancreatic cancer to various medical fields involving the peripheral nervous system. Autonomix is focused on developing a catheter-based microchip sensing array for precise nerve-targeted treatments and is in the investigational stage, not yet cleared for marketing in the U.S.
Potential Positives
- Participation in a Virtual Investor segment highlights the clinical significance of Autonomix's data shared at the Society of Surgical Oncology Annual Meeting, showcasing the company's commitment to advancing treatment options.
- Discussion by Dr. Toufic Kachaamy on the differentiation of Autonomix's approach to managing visceral cancer pain may attract interest from investors and stakeholders in innovative cancer treatments.
- Company's technology platform has the potential for broad applicability beyond pancreatic cancer, indicating future growth opportunities in various medical fields, including cardiology and chronic pain management.
- The suggested capability of the first-in-class platform to enable transvascular diagnosis and treatment could position Autonomix as a leader in precision medicine for diseases involving the peripheral nervous system.
Potential Negatives
- The technology discussed is still in the investigational stage and has not yet been cleared for marketing in the United States, indicating potential delays in commercialization.
- Forward-looking statements raise concerns about the risks and uncertainties associated with the potential effectiveness and clinical benefits of their treatments, highlighting a lack of proven success.
- References to existing treatment techniques suggest that Autonomix's approaches may not yet be competitive or validated in the current market landscape.
FAQ
What is Autonomix Medical's focus in the medical device field?
Autonomix Medical is focused on advancing precision nerve-targeted treatments for diseases involving the nervous system.
Who discussed the clinical significance of Autonomix's data?
Dr. Toufic Kachaamy, Chief of Medicine at City of Hope, discussed the clinical significance of the data presented by Autonomix.
How does Autonomix's technology differ from existing pain treatments?
Autonomix's technology offers a first-in-class platform for more sensitive detection and treatment of neural signals, particularly for visceral cancer pain.
What diseases can Autonomix's platform potentially address?
The platform has the potential to address various conditions, including pancreatic cancer, chronic pain, cardiology, and hypertension.
Where can I access the "What This Means" segment?
The "What This Means" segment can be accessed through the official Autonomix Medical website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AMIX Hedge Fund Activity
We have seen 4 institutional investors add shares of $AMIX stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GEODE CAPITAL MANAGEMENT, LLC added 152,114 shares (+647.1%) to their portfolio in Q1 2026, for an estimated $59,339
- UBS GROUP AG added 33,370 shares (+26275.6%) to their portfolio in Q1 2026, for an estimated $13,017
- XTX TOPCO LTD removed 14,099 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $7,754
- VIRTU FINANCIAL LLC added 12,884 shares (+inf%) to their portfolio in Q1 2026, for an estimated $5,026
- WARBERG ASSET MANAGEMENT LLC removed 11,334 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $6,233
- TWO SIGMA SECURITIES, LLC removed 10,855 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $4,234
- MARINER, LLC removed 233 shares (-0.4%) from their portfolio in Q1 2026, for an estimated $90
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
Dr. Toufic Kachaamy Discusses Visceral Cancer Pain Treatment Differentiation, Pancreatic Cancer Feasibility Data, and Peripheral Nervous System Platform Potential
Access the segment
here
THE WOODLANDS, TX, June 04, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it recently participated in a Virtual Investor “What This Means” segment.
For the segment, Key Opinion Leader and Chief of Medicine at City of Hope in Phoenix, Dr. Toufic Kachaamy, discussed the clinical significance of data presented by Autonomix Medical at the Society of Surgical Oncology Annual Meeting (SSO), highlighting the importance of the work being selected for a podium presentation and its relevance to the surgical oncology community. The segment explored the potential clinical impact of the Company’s approach to managing visceral cancer pain, how it differs from existing treatment techniques, and why those differences may matter in practice. Dr. Kachaamy also addressed the broader applicability of the findings beyond pancreatic cancer and discussed how the results support the ongoing clinical development and feasibility of the technology platform.
The “What This Means” segment can be accessed here .
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit
autonomix.com
and connect with the Company on
X
,
LinkedIn
,
Instagram
and
Facebook
.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release and in the video include, but are not limited to, expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions, the capabilities of the Company's platform technology, and the potential applicability of the technology across multiple indications.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]
